BACIL PHARMA LTD.

Bacil Pharma Ltd has announced that its Board of Directors will convene on October 14, 2026. The primary agenda item is the consideration and approval of the company's unaudited financial results for the half-yearly and quarterly period ending September 30, 2026. The meeting will also address any other business as permitted by the Chairperson.

Bacil Pharma Ltd has announced the closure of its trading window for designated persons, effective October 1st, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will reopen 48 hours after the conclusion of the Board of Directors' meeting, which is scheduled to consider the un-audited financial results for the quarter and half-year ended September 30th, 2026. The exact date of the Board Meeting will be communicated separately to the stock exchanges.

Bacil Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26 and the Notice for its 39th Annual General Meeting (AGM). The AGM is scheduled for September 23rd, 2026, and will be conducted via Video Conference or other audio-visual means (OAVM). Key agenda items include the adoption of the audited financial statements for FY 2025-26 and the re-appointment of Ms. Chaitali Kalpataru Shah as a director retiring by rotation. The report also details changes in the Board of Directors and Key Managerial Personnel (KMP) during the fiscal year, including resignations and appointments.

Bacil Pharma Ltd announced that its Board of Directors met on August 29, 2026. The board approved the notice for the 39th Annual General Meeting (AGM) scheduled for September 23, 2026. Additionally, the Director's Report for the financial year ended March 31, 2026, along with its annexures, was approved. The AGM will be conducted via Video Conferencing/Other Audio Visual Means to transact business as detailed in the notice.

Bacil Pharma Ltd has announced a book closure period from September 17, 2026, to September 23, 2026, inclusive. This closure is for the purpose of the company's 39th Annual General Meeting (AGM), which is scheduled to be held on September 23, 2026. The company has also stated that no dividend has been declared for the financial year 2025-2026. Shareholders are advised to note this period for any administrative purposes related to the AGM.

Bacil Pharma Ltd has announced that its Board of Directors will convene on August 29, 2026. The primary agenda items include discussing the notice for the 39th Annual General Meeting (AGM), approving the Director's Report for the Financial Year 2025-2026, and fixing the date, place, and timing for the 39th AGM. The meeting will also address any other business as permitted by the Chairperson. This notification serves to inform stakeholders about the upcoming board deliberations concerning crucial corporate governance and shareholder engagement activities.

Bacil Pharma Limited announced the appointment of Mr. Mahesh Singh as Non-Executive Independent Director and Mr. Anil Shiv Charan Singh as Non-Executive Director. Both appointments were approved by the Board of Directors at a meeting held on August 25, 2026, and are subject to shareholder approval. The company stated that both appointees have provided necessary declarations and are not debarred from holding directorships. Mr. Singh brings experience in trading, sales, and business development, while Mr. Anil Shiv Charan Singh has expertise in business management and commercial activities, expected to aid strategic decision-making.

Bacil Pharma Limited announced the appointment of two new directors to its Board of Directors during a meeting held on August 25, 2026. Mr. Mahesh Singh has been appointed as a Non-Executive Independent Director, bringing over seven years of experience in trading, product sales, brand establishment, and business development, with expertise in online sales strategies and marketplace expansion. Mr. Anil Shiv Charan Singh has been appointed as a Non-Executive Director, contributing his experience in business management and commercial activities. Both appointments are subject to shareholder approval and the directors have provided necessary declarations and confirmations, confirming they are not debarred from holding office. These appointments aim to strengthen the company's board with diverse expertise.

Bacil Pharma Ltd has announced that its Board of Directors will convene on August 25, 2026. The primary agenda items for this meeting include discussions and approvals related to the appointment of directors and any other business as permitted by the Chairperson. The company has formally intimated the Bombay Stock Exchange (BSE) regarding this scheduled meeting, adhering to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bacil Pharma Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 12, 2026. The company will submit the results to the exchange and make them available on its website. The results will also be published in newspapers in due course. The limited review of the financial results was carried out by the statutory auditors.